Sage Therapeutics to Cut Most Jobs Following Acquisition by Supernus Pharmaceuticals

MT Newswires Live

2025/07/01

Sage Therapeutics (SAGE) is cutting 338 jobs, or the majority of its workforce, after the biotech company agreed to be acquired by Supernus Pharmaceuticals (SUPN), according to government filings in Massachusetts and media reports.

Sage employed 98 people in research and development and 240 in general and administrative roles, the media reports said. The job cuts, effective Aug. 22, were disclosed in a Worker Adjustment and Retraining Notification notice filed on June 26.

On June 16, Supernus agreed to buy Sage for up to $795 million in cash. The deal includes an upfront payment of $8.50 a share, or $561 million, and a non-tradable contingent value right worth up to $3.50 a share, or $234 million, tied to future milestones.

The deal is expected to close in Q3.

Sage and Supernus didn't immediately respond to requests for comment by MT Newswires.

Sage shares fell 0.4% in recent trading Tuesday, and Supernus rose 1.3%.

Price: 9.08, Change: -0.04, Percent Change: -0.44

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548000025"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548000025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548000025?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548000025","market":"sh","top_or_hot":-1,"title":"Sage Therapeutics to Cut Most Jobs Following Acquisition by Supernus Pharmaceuticals","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> (SAGE) is cutting 338 jobs, or the majority of its workforce, after the biotech company agreed to be acquired by <a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> (SUPN), according to government filings in Massachusetts and media reports.</p><p>Sage employed 98 people in research and development and 240 in general and administrative roles, the media reports said. The job cuts, effective Aug. 22, were disclosed in a Worker Adjustment and Retraining Notification notice filed on June 26.</p><p>On June 16, Supernus agreed to buy Sage for up to $795 million in cash. The deal includes an upfront payment of $8.50 a share, or $561 million, and a non-tradable contingent value right worth up to $3.50 a share, or $234 million, tied to future milestones.</p><p>The deal is expected to close in Q3.</p><p>Sage and Supernus didn't immediately respond to requests for comment by MT Newswires.</p><p>Sage shares fell 0.4% in recent trading Tuesday, and Supernus rose 1.3%.</p><p>Price: 9.08, Change: -0.04, Percent Change: -0.44</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics to Cut Most Jobs Following Acquisition by Supernus Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics to Cut Most Jobs Following Acquisition by Supernus Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-01 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> (SAGE) is cutting 338 jobs, or the majority of its workforce, after the biotech company agreed to be acquired by <a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> (SUPN), according to government filings in Massachusetts and media reports.</p><p>Sage employed 98 people in research and development and 240 in general and administrative roles, the media reports said. The job cuts, effective Aug. 22, were disclosed in a Worker Adjustment and Retraining Notification notice filed on June 26.</p><p>On June 16, Supernus agreed to buy Sage for up to $795 million in cash. The deal includes an upfront payment of $8.50 a share, or $561 million, and a non-tradable contingent value right worth up to $3.50 a share, or $234 million, tied to future milestones.</p><p>The deal is expected to close in Q3.</p><p>Sage and Supernus didn't immediately respond to requests for comment by MT Newswires.</p><p>Sage shares fell 0.4% in recent trading Tuesday, and Supernus rose 1.3%.</p><p>Price: 9.08, Change: -0.04, Percent Change: -0.44</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2548000025","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548000025","pubTimestamp":1751381037,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sage Therapeutics  is cutting 338 jobs, or the majority of its workforce, after the biotech company agreed to be acquired by Supernus Pharmaceuticals , according to government filings in Massachusetts and media reports.Sage employed 98 people in research and development and 240 in general and administrative roles, the media reports said. The job cuts, effective Aug. 22, were disclosed in a Worker Adjustment and Retraining Notification notice filed on June 26.On June 16, Supernus agreed to buy Sage for up to $795 million in cash. The deal includes an upfront payment of $8.50 a share, or $561 million, and a non-tradable contingent value right worth up to $3.50 a share, or $234 million, tied to future milestones.The deal is expected to close in Q3.Sage and Supernus didn't immediately respond to requests for comment by MT Newswires.Sage shares fell 0.4% in recent trading Tuesday, and Supernus rose 1.3%.Price: 9.08, Change: -0.04, Percent Change: -0.44","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SAGE":"Sage Therapeutics","SUPN":"Supernus Pharmaceuticals","BK4139":"生物科技"},"translate_title":"Sage Therapeutics被Supernus Pharmaceuticals收购后将裁员大部分","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1,"SAGE":1},"content_text":"Sage Therapeutics (SAGE) is cutting 338 jobs, or the majority of its workforce, after the biotech company agreed to be acquired by Supernus Pharmaceuticals (SUPN), according to government filings in Massachusetts and media reports.Sage employed 98 people in research and development and 240 in general and administrative roles, the media reports said. The job cuts, effective Aug. 22, were disclosed in a Worker Adjustment and Retraining Notification notice filed on June 26.On June 16, Supernus agreed to buy Sage for up to $795 million in cash. The deal includes an upfront payment of $8.50 a share, or $561 million, and a non-tradable contingent value right worth up to $3.50 a share, or $234 million, tied to future milestones.The deal is expected to close in Q3.Sage and Supernus didn't immediately respond to requests for comment by MT Newswires.Sage shares fell 0.4% in recent trading Tuesday, and Supernus rose 1.3%.Price: 9.08, Change: -0.04, Percent Change: -0.44","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}